Cell Communication and Signaling (Mar 2021)

The inhibitory effect of melatonin on human prostate cancer

  • Dexin Shen,
  • Lingao Ju,
  • Fenfang Zhou,
  • Mengxue Yu,
  • Haoli Ma,
  • Yi Zhang,
  • Tongzu Liu,
  • Yu Xiao,
  • Xinghuan Wang,
  • Kaiyu Qian

DOI
https://doi.org/10.1186/s12964-021-00723-0
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Prostate cancer (PCa) is one of the most commonly diagnosed human cancers in males. Nearly 191,930 new cases and 33,330 new deaths of PCa are estimated in 2020. Androgen and androgen receptor pathways played essential roles in the pathogenesis of PCa. Androgen depletion therapy is the most used therapies for primary PCa patients. However, due to the high relapse and mortality of PCa, developing novel noninvasive therapies have become the focus of research. Melatonin is an indole-like neurohormone mainly produced in the human pineal gland with a prominent anti-oxidant property. The anti-tumor ability of melatonin has been substantially confirmed and several related articles have also reported the inhibitory effect of melatonin on PCa, while reviews of this inhibitory effect of melatonin on PCa in recent 10 years are absent. Therefore, we systematically discuss the relationship between melatonin disruption and the risk of PCa, the mechanism of how melatonin inhibited PCa, and the synergistic benefits of melatonin and other drugs to summarize current understandings about the function of melatonin in suppressing human prostate cancer. We also raise several unsolved issues that need to be resolved to translate currently non-clinical trials of melatonin for clinic use. We hope this literature review could provide a solid theoretical basis for the future utilization of melatonin in preventing, diagnosing and treating human prostate cancer. Video abstract

Keywords